Article

Anti-Mullerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization

Department of Obstetrics and Gynecology, Tokyo Medical University, Tokyo, Japan.
Fertility and sterility (Impact Factor: 4.3). 04/2008; 89(3):586-91. DOI: 10.1016/j.fertnstert.2007.03.080
Source: PubMed

ABSTRACT To determine whether the anti-Müllerian hormone (AMH) level in follicular fluid is associated with success in oocyte fertilization during in vitro fertilization (IVF) cycles.
Retrospective study.
Tokyo Medical University hospital.
Thirty-one women undergoing IVF cycles.
The women were divided into two groups according to the success or failure of fertilization. Follicular fluid samples were obtained from a single follicle in each patient.
Assessment of values for AMH, inhibin B, and estradiol from follicular fluid and serum on the day of oocyte retrieval during IVF treatment.
The follicular fluid AMH levels from fertilized patients (group 1) were 3.42 times higher than from nonfertilized (group 2). There was no correlation between the ratio of the high quality grade embryos and either serum AMH or inhibin B levels. There was no statistically significant correlation between serum AMH and the number of oocytes. However, there was a strong correlation between levels of serum estradiol, inhibin B, and the number of oocytes.
Oocytes are more likely to be fertilized when follicles are able to make high concentrations of AMH in the follicular fluid. Thus, AMH could be a prediction marker for fertilization.

1 Bookmark
 · 
69 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This prospective study investigated the relationship between anti-Müllerian hormone (AMH) level in the follicular fluid (FF) and the quality of the oocyte and embryo. A total of 65 FF samples from 54 women were included in this study. FF was collected from the largest preovulatory follicle sized≥20 mm of mean diameter from each ovary. Samples were divided into 3 groups according to the FF AMH levels: below the 33th percentile (low group, FF AMH<2.1 ng/mL, n=21), between the 33th and the 67th percentile (intermediate group, FF AMH=2.1-3.6 ng/mL, n=22), and above the 67th percentile (high group, FF AMH>3.6 ng/mL, n=22). The quality of the ensuing oocytes and embryos was evaluated by fertilization rate and embryo score. FF AMH levels correlated positively with the matched embryo score on day 3 after fertilization (r=0.331, P=0.015). The normal fertilization rate was significantly lower in the low group than in the intermediate group (61.9% vs. 95.5% vs. 77.3%, respectively, P=0.028). Our results suggest that the FF AMH level could be a predictor of the ensuing oocyte and embryo quality.
    Journal of Korean Medical Science 09/2014; 29(9):1266-70. DOI:10.3346/jkms.2014.29.9.1266 · 1.25 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective: To investigate the dynamics of anti-Mullerian hormone (AMH) and inhibin B (INHB) levels during controlled ovarian hyperstimulation (COH) in women with decreased ovarian reserve (DOR), and assess the effect of these dynamic changes on the prediction of clinical outcome in in-vitro fertilization (IVF). Methods: A total of 124 women undergoing IVF cycles were divided into normal ovarian reserve (NOR) and DOR groups. AMH and INHB levels were measured in serum on menstrual cycle day 2 or 3 (D2/3), day 5 of stimulation (D5), hCG day (D-hCG) and follicular fluid (FF) on oocyte retrieval day. Results: Serum AMH levels were gradually decreased while INHB levels were gradually increased from D2/3 to D-hCG during the COH in both groups. Serum AMH, INHB levels on D2/3 and FF AMH, INHB levels were highly positively correlated with AFC and oocytes retrieval. Multivariate logistic regression analysis revealed that clinical pregnancy did not directly correlate with serum and FF AMH and INHB levels. Conclusion: Serum AMH and INHB levels were not directly related to clinical pregnancy, dynamic serum AMH and IHNB levels were positively correlated with COH outcomes.
    Gynecological Endocrinology 01/2015; DOI:10.3109/09513590.2014.998187 · 1.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess whether antimüllerian hormone (AMH) is a predictor of implantation and/or clinical pregnancy in women undergoing assisted reproductive technology. Systematic review and meta-analysis. Not applicable. Women undergoing IVF/intracytoplasmic sperm injection in nondonor cycles. Measurement of serum AMH level. Diagnostic odds ratio (OR) and summary receiver operating characteristic curve (AUC) for AMH as a predictor of implantation and/or clinical pregnancy. A total of 525 observational studies were identified, of which 19 were selected (comprising 5,373 women). Studies reporting clinical pregnancy rates in women with unspecified ovarian reserve (n = 11), diminished ovarian reserve (DOR) (n = 4), and polycystic ovary syndrome (n = 4) were included, together with studies reporting implantation rates (n = 4). The OR for AMH as a predictor of implantation in women with unspecified ovarian reserve (n = 1,591) was 1.83 (95% confidence interval [CI] 1.49-2.25), whereas the AUC was 0.591 (95% CI 0.563-0.618). The OR for AMH as a predictor of clinical pregnancy in these women (n = 4,324) was 2.10 (95% CI 1.82-2.41), whereas the AUC was 0.634 (95% CI 0.618-0.650). The predictive ability of AMH for pregnancy was greatest in women with DOR (n = 615), with OR and AUC of 3.96 (95% CI 2.57-6.10) and 0.696 (95% CI 0.641-0.751), respectively. In contrast, AMH had no significant predictive ability in women with PCOS (n = 414), with OR and AUC of 1.18 (95% CI 0.53-2.62) and 0.600 (95% CI 0.547-0.653), respectively. Antimüllerian hormone has weak association with implantation and clinical pregnancy rates in assisted reproductive technology but may still have some clinical utility in counseling women undergoing fertility treatment regarding pregnancy rates, particularly those with DOR. Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
    Fertility and Sterility 10/2014; DOI:10.1016/j.fertnstert.2014.09.041 · 4.30 Impact Factor